International

Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.

USA
International
image/svg+xml

Media & Investors

Transparency is key at Kuros Biosciences. Explore essential information – from corporate documents to our current share price, all in one place.

Press releases

Here are our latest press releases.
For archived news items, please go to our Resources center. To subscribe to receive our press releases, please click here.

19 Nov 2024

Kuros Biosciences Expands into Extremities Markets

10 Oct 2024

Adhoc Press Release

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

08 Aug 2024

Adhoc Press Release

Kuros Biosciences Reports First Half of 2024 Results

25 Jun 2024

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

24 Apr 2024

Adhoc Press Release

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

17 Apr 2024

Annual General Meeting of Kuros Biosciences approves all resolutions

Investor calendar

Date Event
Mar 11, 2025

Earnings Release FY 2024

Mar 11, 2025

Investor Webcast FY 2024 (3pm CET)

Apr 15, 2025

Annual Shareholders’ Meeting 2025

Apr 17, 2025

Trading Update Q1 2025

Aug 13, 2025

Earnings Release HY1 2025

Aug 14, 2025

Investor Webcast HY1 2025 (3pm CET)

Oct 16, 2025

Trading Update Q3 2025

Reports, Corporate Governance & Meetings

Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.

Reports & Presentations

Corporate Governance

Shareholder Meetings

Regulatory filings

Information on disclosures under the Swiss Stock Exchange Act can be found on the website of the SIX Swiss Exchange website.

Management Transactions

Outstanding Options

Significant Shareholder Transactions

Stabilization

Analysts

For more information regarding analyst reports, please contact:

Laura Pfeifer-Rossi
Octavian AG
sales@octavian.ch
Tel: +41 44 520 1588

Investor Relations

For more information regarding investor
relations, please contact:

Alexandre Müller
Kuros Biosciences
Investor Relations
IR@kurosbio.com
Tel: +41 43 268 32 31

Want to receive our press releases?